**Template #76: Neurotoxicity *(Version [10.1]-[November 2021])***

The following table gives a detailed description of the type of information prompted for by the data entry fields.

| **Line no.** | **Field name** | **Field type**  **Display type** | **Picklist**  **Freetext template** | **Help text** | **Remarks**  **Guidance**  **Cross-reference** |
| --- | --- | --- | --- | --- | --- |
|  | **Administrative data** | **Header 1** |  |  |  |
|  |  | Confidentiality  Display: Basic |  |  |  |
|  | Endpoint | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - neurotoxicity: acute oral - neurotoxicity: short-term oral - neurotoxicity: sub-chronic oral - neurotoxicity: chronic oral - neurotoxicity: oral - neurotoxicity: acute inhalation - neurotoxicity: short-term inhalation - neurotoxicity: sub-chronic inhalation - neurotoxicity: chronic inhalation - neurotoxicity: inhalation - neurotoxicity: acute dermal - neurotoxicity: short-term dermal - neurotoxicity: sub-chronic dermal - neurotoxicity: chronic dermal - neurotoxicity: dermal - neurotoxicity, other | From the picklist select the relevant endpoint addressed by this study summary. In some cases there is only one endpoint title, which may be entered automatically depending on the software application.  If multiple study types are covered by the same data entry form, the specific study type should be selected. If none matches, select the more generic endpoint description '<Generic endpoint>, other' (e.g. Skin irritation / corrosion, other) and give an explanation in the adjacent text field. The generic endpoint title reflects the title of the corresponding OECD Harmonised Template (OHT).  Please note: For (Q)SAR studies the generic endpoint title should be selected, normally with no need to fill in the adjacent text field, as '(Q)SAR' needs to be indicated in field 'Type of information' and the model should be described in field 'Justification of non-standard information' or 'Attached justification'. A specific endpoint title may be used, if addressed by the (Q)SAR information, i.e. the model behind has been validated by experimental data addressing this endpoint.  Note: For the purpose of OHTs, an 'endpoint' is defined in the rather broad sense as an observable or measurable inherent property of a chemical substance which may be specified by the relevant regulatory framework as 'information requirement' (e.g. Boiling point, Sub-chronic toxicity: oral, Fish early-life stage toxicity). In a narrower sense, the term '(eco)toxicity endpoint' refers to an outcome or effect observed in a study. | **Guidance for data migration:** The relevant target phrase is selected as triggered by the value(s) of source fields 'Test type', 'Route of administration' and 'Guideline'. As a fallback a generic phrase is selected, e.g. 'neurotoxicity: oral' or 'neurotoxicity, other', with default supplementary text = value of 'Test type'. |
|  | Type of information | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - experimental study - experimental study planned - experimental study planned (based on read-across) - (Q)SAR - calculation (if not (Q)SAR) - read-across based on grouping of substances (category approach) - read-across from supporting substance (structural analogue or surrogate) - mixture rules calculation - read-across from similar mixture/product - not specified - other: | Select the appropriate type of information, e.g. ' experimental study', ' experimental study planned' or, if alternatives to testing apply, '(Q)SAR', 'read-across ...'. In the case of calculated data, the value 'calculation (if not (Q)SAR)' should only be chosen if the study report does not clearly indicate whether it is based on '(Q)SAR'.  If the information is taken from a handbook or review article, select the relevant item, e.g. ‘experimental study’, if this is provided in the information source. Otherwise select ‘not specified’. Please note: In field ‘Reference type’ the option ‘review article or handbook’ should be selected. In general, the option 'not specified' should be selected if the submitter lacks the knowledge of the type of information. The option 'other:' can be used if another than a pre-defined item applies.  In the case of read-across, follow the instructions related to the relevant legislation, for instance as to whether the (robust) study summary should be entered in a separate data set defined for the read-across (source) substance and referenced in the target substance dataset.  If 'experimental study planned' or 'experimental study planned (based on read-across)' is indicated (in some legislations also defined as 'testing proposal' or 'undertaking of intended submission'), the submitter should include as much information as possible on the planned study in order to support the evaluation of the proposal. Typically, this would include at least the test guideline, information on the test material, the species and the route of administration in the corresponding distinct fields, as appropriate.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on whether specific fields should be completed and/or further details should be attached in field 'Attached background material'. |  |
|  | Adequacy of study | List (picklist)  Display: Basic | **Picklist values:** - key study - supporting study - weight of evidence - disregarded due to major methodological deficiencies - other information | Indicate the adequacy of a (robust) study summary in terms of usefulness for hazard/risk assessment purposes depending on the relevant legislation.  Note: This field is only applicable (or active) if neither 'waiving of standard information' nor 'experimental study planned' has been selected in field 'Type of information'.  Explanation:   - key study: In general, a key study is the study that has been identified as most suitable to describe an endpoint from the perspective of quality, completeness and representativity of data.   - supporting study: Any other adequate study that is considered supportive for the key study or key studies.   - weight of evidence: A record that contributes to a weight of evidence justification for the non-submission of a particular (adequate) study. The weight of evidence justification is normally endpoint-related, i.e. based on all available records included in the weight of evidence evaluation. A short reasoning for why a given record is used in this respect can be provided in field 'Detailed justification / remarks'.   - disregarded due to major methodological deficiencies: study that demonstrates a higher concern than the key study/ies, but is not used as key study because of flaws in the methodology or documentation. This phrase should be selected for justifying why a potentially critical result has not been used for the hazard assessment. The lines of argumentation should be provided in field 'Rationale for reliability incl. deficiencies', accompanied by the appropriate reliability score.  - other information: any other non-relevant information which does not need to be flagged specifically as 'disregarded due to major methodological deficiencies'.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. | **Guidance for field condition:** Condition: Field active only if 'Type of information' is not 'experimental study planned' and not ‘experimental study planned (based on read-across)’ and field 'Data waiving' is not populated (except for migrated data) |
|  | Robust study summary | Check box  Display: Basic |  | Set this flag if relevant for the respective regulatory programme or if otherwise useful as filter for printing or exporting records flagged as 'Robust Study Summary' or in combination with 'Adequacy of study'.   Explanation: The term 'Robust Study Summary' is actually used only to describe the technical content of a very detailed summary of an experimental study or of any other relevant information. It is a priori no synonym with the term 'Key study', although a key study should usually be submitted in the form of Robust Study Summary. However, a Robust Summary may also be useful for other adequate studies that are considered supportive of the key study or even for inadequate studies if they can be used for a weight-of-evidence analysis. Also for studies that are flawed, but indicate critical results, Robust Study Summaries highlighting the weaknesses of the studies need to be elaborated.   Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. |  |
|  | Used for classification | Check box  Display: Basic |  | Set this flag if relevant for the respective regulatory programme or if otherwise useful as filter for printing or exporting records flagged as 'Used for classification'.  Explanation: In some use cases it may be necessary to indicate those records that are used for the classification of that substance, e.g. according to UN GHS. If not relevant, disregard this field.   Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. |  |
|  | Used for SDS | Check box  Display: Basic |  | Set this flag if relevant for the respective regulatory programme or if otherwise useful as filter for printing or exporting records flagged as 'SDS information'.   Explanation: 'SDS' stands for Safety Data Sheet. In some use cases it may be necessary to indicate those records that are used for the compilation of SDS information. If not relevant, disregard this field.   Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. |  |
|  | Study period | Text (255 char.)  Display: Basic |  | If applicable indicate the period during which the study was conducted, i.e. start and end date, using an unambiguous date format, e.g. 'From 12 MAY 1999 to 15 AUG 2000' or 'From May 12, 1999 to Aug. 15, 2000'.   Note: Independent of the study period the in-life period (i.e. the phase of a study following treatment in which the test system is alive/growing) may have to be specified for some toxicology endpoints. |  |
|  | Reliability | List (picklist)  Display: Basic | **Picklist values:** - 1 (reliable without restriction) - 2 (reliable with restrictions) - 3 (not reliable) - 4 (not assignable) - other: | Enter an appropriate reliability score, according to Klimisch et al. (1997):  1 = reliable without restrictions: “studies or data [...] generated according to generally valid and/or internationally accepted testing guidelines (preferably performed according to GLP) or in which the test parameters documented are based on a specific (national) testing guideline [...] or in which all parameters described are closely related/comparable to a guideline method.”  2 = reliable with restrictions: “studies or data [...] (mostly not performed according to GLP), in which the test parameters documented do not totally comply with the specific testing guideline, but are sufficient to accept the data or in which investigations are described which cannot be subsumed under a testing guideline, but which are nevertheless well documented and scientifically acceptable.”  3 = not reliable: “studies or data [...] in which there were interferences between the measuring system and the test substance or in which organisms/test systems were used which are not relevant in relation to the exposure (e.g. non-physiological pathways of application) or which were carried out or generated according to a method which is not acceptable, the documentation of which is not sufficient for assessment and which is not convincing for an expert judgment.”  4 = not assignable: “studies or data [...] which do not give sufficient experimental details and which are only listed in short abstracts or secondary literature (books, reviews, etc.).”  The 'other:' option may be selected if a different scoring system is used. Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field.  Note: This field is only applicable (or active) if neither 'waiving of standard information' nor 'experimental study planned' has been selected in field 'Type of information'.  Note: The term reliability defines the inherent quality of a test report or publication relating to preferably standardised methodology and the way the method and results are described. More detailed criteria can be selected in field 'Justification'. |  |
|  | Rationale for reliability incl. deficiencies | List sup. (picklist with remarks - 32,000 char.)  Display: Basic | **Picklist values:** - guideline study - [Reliability 1] - comparable to guideline study - [Reliability 1] - test procedure in accordance with national standard methods - [Reliability 1] - test procedure in accordance with generally accepted scientific standards and described in sufficient detail - [Reliability 1] - guideline study without detailed documentation - [Reliability 2] - guideline study with acceptable restrictions - [Reliability 2] - comparable to guideline study with acceptable restrictions - [Reliability 2] - test procedure in accordance with national standard methods with acceptable restrictions - [Reliability 2] - study well documented, meets generally accepted scientific principles, acceptable for assessment - [Reliability 2] - accepted calculation method - [Reliability 2] - data from handbook or collection of data - [Reliability 2] - significant methodological deficiencies - [Reliability 3] - unsuitable test system - [Reliability 3] - abstract - [Reliability 4] - secondary literature - [Reliability 4] - documentation insufficient for assessment - [Reliability 4] - results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification - [Reliability 1 or 2] - results derived from a valid (Q)SAR model and falling into its applicability domain, with limited documentation / justification - [Reliability 2, 3 or 4] - results derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, with adequate and reliable documentation / justification - [Reliability 2 or 3] - results derived from a (Q)SAR model, with limited documentation / justification, but validity of model and reliability of prediction considered adequate based on a generally acknowledged source - [Reliability 2 or 3] - results derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited - [Reliability 3 or 4] - results derived from a (Q)SAR model, with limited documentation / justification - [Reliability 4] - other: | Select an appropriate standard justification from the picklist, e.g. 'Comparable to guideline study with acceptable restrictions'. Additional explanations (e.g. deficiencies observed) can be entered in the related supplementary text field. Particularly if reliability scores 2 or 3 are assigned, indicate the concrete arguments for defending a study or relevant deficiencies.  For QSAR results (i.e. 'Type of information' is '(Q)SAR') some pre-defined phrases are provided for indicating if the prediction results are considered reliable based on the scientifically validity of the (Q)SAR model used, its applicability to the query substance, and the adequacy of reporting. Please note: If (Q)SAR results are flagged as key study in field 'Adequacy of study', the relevance of the model used for the regulatory endpoint should be documented in the field where the (Q)SAR model is described, i.e. 'Justification for type of information', 'Attached justification' or 'Cross-reference'. | **Guidance for field condition:** Condition: Field active only if 'Type of information' is not 'experimental study planned' and not ‘experimental study planned (based on read-across)’. Condition 1: If 'Type of information' is not '(Q)SAR': - guideline study - [Reliability 1] - comparable to guideline study - [Reliability 1] - test procedure in accordance with national standard methods - [Reliability 1] - test procedure in accordance with generally accepted scientific standards and described in sufficient detail - [Reliability 1] - guideline study without detailed documentation - [Reliability 2] - guideline study with acceptable restrictions - [Reliability 2] - comparable to guideline study with acceptable restrictions - [Reliability 2] - test procedure in accordance with national standard methods with acceptable restrictions - [Reliability 2] - study well documented, meets generally accepted scientific principles, acceptable for assessment - [Reliability 2] - accepted calculation method - [Reliability 2] - data from handbook or collection of data - [Reliability 2] - significant methodological deficiencies - [Reliability 3] - unsuitable test system - [Reliability 3] - abstract - [Reliability 4] - secondary literature - [Reliability 4] - documentation insufficient for assessment - [Reliability 4] Condition 2: If 'Type of information' = '(Q)SAR': - results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification - [Reliability 1 or 2] - results derived from a valid (Q)SAR model and falling into its applicability domain, with limited documentation / justification - [Reliability 2, 3 or 4] - results derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, with adequate and reliable documentation / justification - [Reliability 2 or 3] - results derived from a (Q)SAR model, with limited documentation / justification, but validity of model and reliability of prediction considered adequate based on a generally acknowledged source - [Reliability 2 or 3] - results derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited - [Reliability 3 or 4] - results derived from a (Q)SAR model, with limited documentation / justification - [Reliability 4] - other: |
|  | Data waiving | List (picklist)  Display: Basic | **Picklist values:** - study technically not feasible - study scientifically not necessary / other information available - exposure considerations - study waived due to provisions of other regulation - other justification | If appropriate, indicate here that the study has been waived, i.e. not performed. Select the basis from the picklist (e.g. 'study technically not feasible' or 'other justification'). Include a more detailed justification in the field 'Justification for data waiving' and, as needed, in field 'Justification for type of information', 'Attached justification' and/or 'Cross-reference'. Please note: the option 'study scientifically not necessary / other information available' covers cases where it can be justified that performance of a specific study prescribed by the relevant legislation is scientifically not necessary because reliable information is provided in other part(s) of the submission document.  The option 'study waived due to provisions of other regulation' can be used for indicating that another, overlapping regulation allows or requires the waiving of a specific information requirement. This should then be detailed in the justification fields.  If waiving is based on several lines of argumentation (e.g. ‘exposure considerations’ and ‘study scientifically not necessary / other information available’), create separate records for each.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use data waivers. | **Guidance for field condition:** Condition: Deactivate this field if any of the following fields is populated: 'Type of information', 'Adequacy of study', 'Reliability', 'Rationale for reliability'. |
|  | Justification for data waiving | List multi. (multi-select list with remarks - 32,000 char.)  Display: Basic | **Picklist values:** - other: | In addition to the more generic justification selected in the preceding field 'Data waiving', it is highly recommended to provide a detailed justification. To this end you can either select one or multiple specific standard phrase(s) if it/they give an appropriate rationale of the description given in the preceding field 'Data waiving' or 'other:' and enter free text. Additional specific explanations should be provided if the pre-defined phrase(s) do no sufficiently describe the justification.  More details can be provided using the following fields:  - Text field adjacent to this field 'Justification for data waiving' (available after selecting any picklist item in this field);  - Field 'Justification for type of information';  - Field 'Attached justification';  - Cross-reference (for referencing / linking to a justification or information referred to in the justification which is stored in another record, e.g. a record describing physico-chemical properties information used to support a data waiver)  Please note: The pre-defined phrases are not necessarily exhaustive and may not always apply. Consult the guidance documents and waiving options in the relevant regulatory frameworks. If no suitable phrase is available from the picklist, enter a free text justification using the 'other:' option. | **Guidance for field condition:** Condition: Deactivate this field if any of the following fields is populated: 'Type of information', 'Adequacy of study', 'Reliability', 'Rationale for reliability'. |
|  | Justification for type of information | Text template  Display: Basic | **Freetext template:  Option 1 Type 'Waiving of standard information'** JUSTIFICATION FOR DATA WAIVING [Specific explanation in addition to field 'Justification for data waiving'] **Option 2 Type 'Experimental study planned / Testing proposal on vertebrate animals'** TESTING PROPOSAL ON VERTEBRATE ANIMALS [Please provide information for all of the points below. The information should be specific to the endpoint for which testing is proposed. Note that for testing proposals addressing testing on vertebrate animals under the REACH Regulation this document will be published on the ECHA website along with the third party consultation on the testing proposal(s).]  NON-CONFIDENTIAL NAME OF SUBSTANCE: - Name of the substance on which testing is proposed to be carried out - Name of the substance for which the testing proposal will be used [if different from tested substance]  CONSIDERATIONS THAT THE GENERAL ADAPTATION POSSIBILITIES OF ANNEX XI OF THE REACH REGULATION ARE NOT ADEQUATE TO GENERATE THE NECESSARY INFORMATION [please address all points below]: - Available GLP studies - Available non-GLP studies - Historical human/control data - (Q)SAR - In vitro methods - Weight of evidence - Grouping and read-across - Substance-tailored exposure driven testing [if applicable] - Approaches in addition to above [if applicable] - Other reasons [if applicable]  CONSIDERATIONS THAT THE SPECIFIC ADAPTATION POSSIBILITIES OF ANNEXES VI TO X (AND COLUMN 2 THEREOF) OF THE REACH REGULATION ARE NOT ADEQUATE TO GENERATE THE NECESSARY INFORMATION: - [free text]  FURTHER INFORMATION ON TESTING PROPOSAL IN ADDITION TO INFORMATION PROVIDED IN THE MATERIALS AND METHODS SECTION: - Details on study design / methodology proposed [if relevant] **Option 3 Type 'QSAR prediction'** 1. SOFTWARE  2. MODEL (incl. version number)  3. SMILES OR OTHER IDENTIFIERS USED AS INPUT FOR THE MODEL  4. SCIENTIFIC VALIDITY OF THE (Q)SAR MODEL [[Explain how the model fulfils the OECD principles for (Q)SAR model validation. Consider attaching the QMRF and/or QPRF or providing a link] - Defined endpoint: - Unambiguous algorithm: - Defined domain of applicability: - Appropriate measures of goodness-of-fit and robustness and predictivity: - Mechanistic interpretation:  5. APPLICABILITY DOMAIN [Explain how the substance falls within the applicability domain of the model] - Descriptor domain: - Structural domain: - Mechanistic domain: - Similarity with analogues in the training set: - Other considerations (as appropriate):  6. ADEQUACY OF THE RESULT [Explain how the prediction fits the purpose of classification and labelling and/or risk assessment] **Option 4 Type 'Read-across (analogue)'** REPORTING FORMAT FOR THE ANALOGUE APPROACH [Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]  1. HYPOTHESIS FOR THE ANALOGUE APPROACH [Describe why the read-across can be performed (e.g. common functional group(s), common precursor(s)/breakdown product(s) or common mechanism(s) of action]  2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES) [Provide here, if relevant, additional information to that included in the Test material section of the source and target records]  3. ANALOGUE APPROACH JUSTIFICATION [Summarise here based on available experimental data how these results verify that the read-across is justified]  4. DATA MATRIX **Option 5 Type 'Read-across (category)'** REPORTING FORMAT FOR THE CATEGORY APPROACH [Please provide information for all of the points below addressing endpoint-specific elements that were not already covered by the overall category approach justification made available at the category level. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]  1. HYPOTHESIS FOR THE CATEGORY APPROACH (ENDPOINT LEVEL) [Describe why the read-across can be performed]  2. CATEGORY APPROACH JUSTIFICATION (ENDPOINT LEVEL [Summarise here based on available experimental data how these results verify that the read-across is justified] | This field can be used for entering free text. As appropriate, one of the freetext templates can be selected (e.g. Justification for read-across (analogue)) to use pre-defined headers and bulleted elements. Delete/add elements as appropriate.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on what should be taken into account when providing justifications or whether specific reporting formats should be used.  Explanations:  Option 1: Type 'Waiving of standard information':  This field should be used for entering any further lines of argumentation, if necessary, in addition to those provided in the field 'Justification for data waiving'.  Option 2: Type 'Experimental study planned / Testing proposal':  Further details can be entered here on the study design / methodology proposed in addition to details given in the distinct fields on test guideline, test material, species, route of administration and other relevant fields.  Option 3: Type 'QSAR prediction':  Based on this freetext template details on the QSAR model used can be given, in addition to the information provided in field 'Principles of method if other than guideline'.  Please note: Any information that can be re-used for several study summaries can be entered once and then assigned to the relevant studies using either the 'Attached justification' or 'Cross-reference' feature.  Option 4: Type 'Read-across (analogue)' and Option 5: Type 'Read-across (category)'  This freetext template can be used and modified as appropriate for providing a justification for read-across, particularly if it is endpoint-specific.  Please note: Any information that can be re-used for several study summaries can be entered once and then assigned to the relevant studies using either the 'Attached justification' or 'Cross-reference' feature. |  |
|  | **Attached justification** | **Block of fields (repeatable) Start** |  | The Attached justification feature can be used in case the justification is best provided in form of attached document(s).  Copy this block of fields for attaching more than one file.  Refer to the relevant legislation-specific guidance document as to the recommended use of the Attached justification feature. |  |
|  | Attached justification | Attachment (single)  Display: Basic |  | Upload file by clicking the upload icon. |  |
|  | Reason / purpose | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - data waiving: supporting information - exposure-related information - read-across: supporting information - (Q)SAR model reporting (QMRF) - (Q)SAR prediction reporting (QPRF) - (Q)SAR model and prediction reporting (QMRF/QPRF) - (Q)SAR: supporting information - justification, other: | Indicate the reason for / purpose of the attached document. Select the relevant item from the picklist or, if none applies, select 'justification, other:' and specify. |  |
|  | **Attached justification** | **Block of fields (repeatable) End** |  |  |  |
|  | **Cross-reference** | **Block of fields (repeatable) Start** |  | The cross-reference feature can be used to refer to related information that is provided in another record of the dataset. This can be done either by entering just free text in the 'Remarks' field or by creating a link to the relevant record. The field 'Reason / purpose' allows for selecting a standard reason from the picklist and optionally to add free text explanation in the related supplementary text field.  Refer to the relevant legislation-specific guidance document as to the recommended use of cross-references. |  |
|  | Reason / purpose for cross-reference | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - assessment report - data waiving: supporting information - exposure-related information - read-across source - read-across: supporting information - (Q)SAR model reporting (QMRF) - reference to other assay used for intermediate effect derivation - reference to same study - reference to other study - other: | Select the appropriate reason of the cross-reference, i.e.  - assessment report (for referring to a record that contains an assessment report as attachment)  - data waiving: supporting information (for referring to a record containing relevant endpoint information that is used to justify a data waiver)  - exposure-related information (for referring to a record containing exposure-related information that is used for instance to justify a data waiver)  - read-across source (for linking to another study summary used for read-across. This can be useful in cases where results are derived from one or several read-across sources and recorded in a separate (target) study summary.)  - read-across supporting information (for linking to another record which contains read-across justification that applies also for the current study summary)  - (Q)SAR model reporting (OMRF) (for referring to a record containing the relevant model description. Note: The (Q)SAR prediction should be reported specifically for each endpoint in the field 'Justification for type of information'.)  - reference to other assay used for intermediate effect derivation (for optional indication in a study summarising 'intermediate effects' if reference is made to the outcome of another assay)  - reference to same study (e.g. if different species were tested and the results recorded in different records),   - reference to other study (e.g. if another study is considered relevant in the interpretation of the test results),   - other: (to be specified). |  |
|  | Related information | Link to endpoint (single)  Display: Basic |  | As appropriate, select the record containing the related information, thus creating a link. | **Cross-reference:** AllSummariesAndRecords |
|  | Remarks | Text (32,768 char.)  Display: Basic |  | This field can be used for including any remarks. |  |
|  | **Cross-reference** | **Block of fields (repeatable) End** |  |  |  |
|  | **Data source** | **Header 1** |  |  |  |
|  | Reference | Link to lit. reference (multiple)  Display: Basic |  | Indicate the bibliographic reference of the study report or publication the study summary is based on. Provide general information such as Title, Author, Year, Bibliographic source, Testing Facility, Report Number, Study number, Report date etc., as requested in the core template for literature search (http://www.oecd.org/ehs/templates/Generic%20elements%20for%20all%20OHTs%20(added%20online%20Feb%202017).zip).   Always enter the primary reference in the first block of fields or sort it to the first position, if there are more than one reference to be cited. Copy this block of fields for specifying any other references related to this record (e.g. report of a preliminary study or other documentation). If results of a study report have been published, indicate the full citation of that publication(s) in addition to the reference of the original study. |  |
|  | Data access | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - data submitter is data owner - data submitter has Letter of Access - data no longer protected - data published - data submitter has permission to refer - not applicable - other: | Select appropriate indication for data access. Enter 'Not applicable' if the summary consists of information that is commonly accessible such as guidance on safe use.  Select 'data submitter has permission to refer' if the information requirement can be covered based on a permission to refer to old data as issued by the relevant regulatory agency. In addition, provide, in the adjacent free-text field, the statement according to instructions you received from the relevant regulatory authority together with the permission to refer. |  |
|  | Data protection claimed | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - yes - yes, but willing to share - yes, but not willing to share | Indicate as appropriate. Note: 'yes' should be selected only if 'Data submitter is data owner' or 'Data submitter has Letter of Access'. Options 'yes, but willing to share' or 'yes, but not willing to share' may be relevant for specific regulatory programmes where the submitter is requested to indicate whether he is willing to share studies conducted (e.g. with vertebrates).  In the supplementary remarks field, include an explanation as appropriate, i.e. justification for denial of sharing the corresponding study or refer to a document attached that provides justification (e.g. 'for justification see attached document X') |  |
|  | **Materials and methods** | **Header 1** |  |  |  |
|  | **Test guideline** | **Block of fields (repeatable) Start** |  | Indicate according to which test guideline the study was conducted. If no test guideline was explicitly followed, but the methodology used is equivalent or similar to a specific guideline, you can indicate so in the 'Qualifier' subfield preceding the field 'Guideline'.  Copy this block of fields for specifying more than one guideline (e.g. US EPA in addition to OECD guideline). |  |
|  | Qualifier | List (picklist)  Display: Basic | **Picklist values:** - according to guideline - equivalent or similar to guideline - no guideline followed - no guideline available - no guideline required | Select appropriate qualifier, i.e.  - 'according to guideline' (if a given test guideline was followed);  - 'equivalent or similar to guideline' (if no test guideline was explicitly followed, but the methodology is equivalent or similar to a specific guideline);  - 'no guideline followed' (if none of above qualifiers apply. If so, fill in field 'Principles of method if other than guideline');  - 'no guideline available' (if so, fill in field 'Principles of method if other than guideline').  - 'no guideline required' (if so, fill in field 'Principles of method if other than guideline'). |  |
|  | Guideline | List (picklist)  Display: Basic | **Picklist values:** - OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents) - OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents) - OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study) - [./.] - OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study) - [before 9 October 2017] - OECD Guideline 413 (90-Day (Subchronic) Inhalation Toxicity Study - [from 9 October 2017] - OECD Guideline 418 (Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure) - OECD Guideline 419 (Delayed Neurotoxicity of Organophosphorus Substances: 28-Day Repeated Dose Study) - OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test) - OECD Guideline 424 (Neurotoxicity Study in Rodents) - OECD Guideline 426 (Developmental Neurotoxicity Study) - OECD Guideline 443 (Extended One-Generation Reproductive Toxicity Study) - EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral)) - EU Method B.8 (Subacute Inhalation Toxicity: 28-Day Study) - [./.] - EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents) - EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study) - [./.] - EU Method B.30 (Chronic Toxicity Studies) - [./.] - EU Method B.33 (Combined Chronic Toxicity / Carcinogenicity Test) - EU Method B.37 (Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure) - EU Method B.38 (Delayed Neurotoxicity of Organophosphorus Substances 28-Day Repeated Dose Study) - EU Method B.43 (Neurotoxicity Study in Rodents) - EU Method B.53 (Developmental Neurotoxicity Study) - EU Method B.56 (Extended One-Generation Reproductive Toxicity Study) - EPA OPP 81-7 (Delayed Neurotoxicity of Organophosphorus Substances Following Acute and 28-Day Exposure) - EPA OPP 81-8 (Neurotoxicity Screening Battery) - EPA OPP 82-4 (90-Day Inhalation Toxicity) - EPA OPP 83-1 (Chronic Toxicity) - EPA OPP 83-6 (Developmental Neurotoxicity Study) - EPA OPP 85-5 (Schedule-Controlled Neurotoxicity Study) - EPA OPP 85-6 (Peripheral Nerve Function) - EPA OPPTS 870.3465 (90-Day Inhalation Toxicity) - EPA OPPTS 870.3600 (Inhalation Developmental Toxicity Screen) - EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study) - EPA OPPTS 870.4100 (Chronic Toxicity) - EPA OPPTS 870.6100 (Acute and 28-Day Delayed Neurotoxicity of Organophosphorus Substances) - EPA OPPTS 870.6200 (Neurotoxicity Screening Battery) - EPA OPPTS 870.6300 (Developmental Neurotoxicity Study) - EPA OPPTS 870.6500 (Schedule-Controlled Neurotoxicity Study) - EPA OPPTS 870.6850 (Peripheral Nerve Function) - EPA OPPTS 870.6855 (Neurophysiology: Sensory Evoked Potentials) - EPA OTS 795.2500 (Developmental Neurotoxicity Screen) - EPA OTS 798.2450 (90-Day Inhalation Toxicity) - EPA OTS 798.3260 (Chronic Toxicity) - EPA OTS 798.6050 (Neurotoxicity Screening Battery) - EPA OTS 798.6450 (Acute and 28-Day Delayed Neurotoxicity of Organophosphorus Substances) - EPA OTS 798.6500 (Schedule-Controlled Neurotoxicity Study) - EPA OTS 798.6540 (Acute and 28-Day Delayed Neurotoxicity of Organophosphorus Substances) - EPA OTS 798.6560 (Acute and 28-Day Delayed Neurotoxicity of Organophosphorus Substances) - EPA OTS 798.6850 (Peripheral Nerve Function) - EPA OTS 798.6855 (Neurophysiology: Sensory Evoked Potentials) - other: | Select the applicable test guideline, e.g. 'OECD Guideline xxx'. If the test guideline used is not listed, choose 'other:' and specify the test guideline in the related text field. Information on the version and date of the guideline used and/or any other specifics can be entered in the next field 'Version / remarks'.  If no test guideline can be specified, this should be indicated in the preceding field 'Qualifier'. The method used should then be shortly described in the field 'Principles of method if other than guideline', while details can be given in other distinct fields.  Please note: Test guidelines used for the validation of (Q)SAR models should be reported in the description of the relevant model in field 'Justification for type of information' or 'Attached justification'. | **Guidance for field condition:** Condition: Field active only if 'Qualifier' is not 'no guideline ...' |
|  | Version / remarks | Text (2,000 char.)  Display: Basic |  | In this text field, you can enter any remarks as applicable, particularly:  - To include any other title of the test guideline draft used, a subtitle, another version or update number and the year of update (For instance, different titles and/or numbers may exist for a given EU test guideline);  - To indicate if the study was performed prior to the adoption of the test guideline specified;  - To indicate if the methodology used was based on an extension of the test guideline specified;  - To indicate what protocol was followed for methods that allow the optional determination of more than one parameter if this cannot be indicated in a distinct field of the Materials and methods section. | **Guidance for field condition:** Condition: Field active only if 'Qualifier' is not 'no guideline ...' |
|  | Deviations | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - yes - no - not applicable - not specified | In case a test guideline or other standardised method was used, indicate if there are any deviations. Briefly state relevant deviations in the supplementary remarks field (e.g. 'other test system used', 'different exposure duration'); details should be described in the respective fields of the section MATERIALS AND METHODS. | **Guidance for field condition:** Condition: Field active only if 'Qualifier' is not 'no guideline ...' |
|  | **Test guideline** | **Block of fields (repeatable) End** |  |  |  |
|  | Principles of method if other than guideline | Text template  Display: Basic | **Freetext template:  Option 1 Method of non-guideline study** - Principle of test: - Short description of test conditions: - Parameters analysed / observed: **Option 2 (Q)SAR** - Software tool(s) used including version: - Model(s) used: - Model description: see field 'Justification for non-standard information', 'Attached justification' and/or 'Cross-reference' - Justification of QSAR prediction: see field 'Justification for type of information', 'Attached justification' and/or 'Cross-reference' | If no guideline was followed, include a description of the principles of the test protocol or estimated method used in the study. As appropriate use either of the pre-defined freetext template options for 'Method of non-guideline study' or '(Q)SAR'. Delete / add elements and edit text set in square brackets [...] as appropriate.  For a non-guideline experimental study a high-level freetext template can be used for summarising the principle of test, test conditions and parameters analysed / observed.   If the freetext template for (Q)SAR is selected, indicate the QSAR model(s) or platform including version and the software tool(s) used. Detailed justification of the model and prediction should be provided in field(s) 'Justification for type of information', 'Attached justification' and/or 'Cross-reference' as appropriate.  Details should be entered in appropriate distinct fields of section MATERIALS AND METHODS if available. Also provide a justification for using this method if appropriate. |  |
|  | GLP compliance | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - yes (incl. QA statement) - yes - no - not specified | Indicate whether the study was conducted following Good Laboratory Practice or not. In case 'yes’ is selected, a Quality Assurance (QA) statement must be provided with the report. You can give an explanation in the supplementary remarks field, e.g. for explaining why GLP was not complied with or for specifying which (national) GLP was followed. |  |
|  | Limit test | List (picklist)  Display: Basic | **Picklist values:** - yes - no | Indicate if the experiment was a limit test. |  |
|  | **Test material** | **Header 2** |  |  |  |
|  | Test material information | Link to entity (single)  Display: Basic |  | Select the appropriate Test Material Information (TMI) record. If not available in the repository, create a new one. You may also copy (clone) an existing TMI record, edit it and store it as new TMI.  To change the link to an existing TMI, click the Delete button, then the Link button and proceed as described above.  Depending on the purpose of the reporting or data submission, the information that must be provided may change. As a minimum, the chemical name, identifier and/or CAS number and molecular weight must be provided. | **Cross-reference:** TEST\_MATERIAL\_INFORMATION |
|  | Additional test material information | Link to entity (multiple)  Display: Basic |  | Select additional Test material information record if relevant. For example, in longer terms studies more than one batch of test material can be needed or there may be differences between the labelled and unlabelled test materials. | **Cross-reference:** TEST\_MATERIAL\_INFORMATION |
|  | Specific details on test material used for the study | Text template  Display: Basic | **Freetext template:** SOURCE OF TEST MATERIAL - Source (i.e. manufacturer or supplier) and lot/batch number of test material: - Purity, including information on contaminants, isomers, etc.:  RADIOLABELLING INFORMATION (if applicable) - Radiochemical purity: - Specific activity: - Locations of the label: - Expiration date of radiochemical substance:  STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL - Storage condition of test material: - Stability and homogeneity of the test material in the vehicle/solvent under test conditions (e.g. in the exposure medium) and during storage: - Stability in the medium, i.e. sensitivity of the test material to hydrolysis and/or photolysis: - Solubility and stability of the test material in the solvent/vehicle and the exposure medium: - Reactivity of the test material with the incubation material used (e.g. plastic ware):  TREATMENT OF TEST MATERIAL PRIOR TO TESTING - Treatment of test material prior to testing (e.g. warming, grinding): - Preliminary purification step (if any): - Final concentration of a dissolved solid, stock liquid or gel: - Final preparation of a solid (e.g. stock crystals ground to fine powder using a mortar and pestle):  FORM AS APPLIED IN THE TEST (if different from that of starting material) - Specify the relevant form characteristics if different from those in the starting material, such as state of aggregation, shape of particles or particle size distribution:  INFORMATION ON NANOMATERIALS - Chemical Composition: - Density: - Particle size & distribution: - Specific surface area: - Isoelectric point: - Dissolution (rate):  TYPE OF BIOCIDE/PESTICIDE FORMULATION (if applicable) - Description of the formulation, e.g. formulated product for foliar application; formulated product soil application; solution in organic solvent for soil application; formulated product seed treatment; solution in organic solvent seed treatment:  OTHER SPECIFICS - Other relevant information needed for characterising the tested material, e.g. if radiolabelled, adjustment of pH, osmolality and precipitate in the culture medium to which the test chemical is added: | Use this field for reporting specific details on the test material as used for the study if they differ from the starting material specified under 'Test material information'. This can include information on the pre-defined items, but not all or additional ones may be relevant.  Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  If applicable, relevant available information on the following items should be given:  SOURCE OF TEST MATERIAL  - Source and lot/batch No. of test material  - Expiration date of the lot/batch  - Purity test date: provide if available  RADIOLABELLING INFORMATION  - Radiochemical purity  - Specific activity  - Locations of the label  - Expiration date of radiochemical substance  STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL  - Storage condition of test material  - Stability under test conditions  - Solubility and stability of the test substance in the solvent/vehicle  - Reactivity of the test substance with the solvent/vehicle or the cell culture medium  TREATMENT OF TEST MATERIAL PRIOR TO TESTING  - Treatment of test material prior to testing (e.g. warming, grinding)  - Preliminary purification step  - Final dilution of a soluble solid, stock liquid, or gel (e.g., neat liquid, stock diluted liquid, or dissolved solid) to final concentration and the solvent(s) used  - Final preparation of a solid (e.g. stock crystals ground to fine powder using a mortar and pestle)  FORM AS APPLIED IN THE TEST (if different from that of starting material)  Specify the relevant form characteristics if different from those in the starting material, such as state of aggregation, shape of particles or particle size distribution.  FORMULATED PRODUCT (for biocides/pesticides)  Description of the formulation, e.g. formulated product for foliar application; formulated product soil application; solution in organic solvent for soil application: formulated product seed treatment; solution in organic solvent seed treatment.  OTHER SPECIFICS  Provide any other relevant information needed for characterising the tested material. |  |
|  | Specific details on test material used for the study (confidential) | Text template  Display: Basic (Confidential) | **Freetext template:** SOURCE OF TEST MATERIAL - Source (i.e. manufacturer or supplier) and lot/batch number of test material: - Purity, including information on contaminants, isomers, etc.:  RADIOLABELLING INFORMATION (if applicable) - Radiochemical purity: - Specific activity: - Locations of the label: - Expiration date of radiochemical substance:  STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL - Storage condition of test material: - Stability and homogeneity of the test material in the vehicle/solvent under test conditions (e.g. in the exposure medium) and during storage: - Stability in the medium, i.e. sensitivity of the test material to hydrolysis and/or photolysis: - Solubility and stability of the test material in the solvent/vehicle and the exposure medium: - Reactivity of the test material with the incubation material used (e.g. plastic ware):  TREATMENT OF TEST MATERIAL PRIOR TO TESTING - Treatment of test material prior to testing (e.g. warming, grinding): - Preliminary purification step (if any): - Final concentration of a dissolved solid, stock liquid or gel: - Final preparation of a solid (e.g. stock crystals ground to fine powder using a mortar and pestle):  FORM AS APPLIED IN THE TEST (if different from that of starting material) - Specify the relevant form characteristics if different from those in the starting material, such as state of aggregation, shape of particles or particle size distribution:  INFORMATION ON NANOMATERIALS - Chemical Composition: - Density: - Particle size & distribution: - Specific surface area: - Isoelectric point: - Dissolution (rate):  TYPE OF BIOCIDE/PESTICIDE FORMULATION (if applicable) - Description of the formulation, e.g. formulated product for foliar application; formulated product soil application; solution in organic solvent for soil application; formulated product seed treatment; solution in organic solvent seed treatment:  OTHER SPECIFICS - Other relevant information needed for characterising the tested material, e.g. if radiolabelled, adjustment of pH, osmolality and precipitate in the culture medium to which the test chemical is added: | Use this field for reporting specific details on the test material as used for the study if they differ from the starting material specified under 'Test material information'. This can include information on the pre-defined items, but not all or additional ones may be relevant.  Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  If applicable, relevant available information on the following items should be given:  SOURCE OF TEST MATERIAL  - Source and lot/batch No. of test material  - Expiration date of the lot/batch  - Purity test date: provide if available  RADIOLABELLING INFORMATION  - Radiochemical purity  - Specific activity  - Locations of the label  - Expiration date of radiochemical substance  STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL  - Storage condition of test material  - Stability under test conditions  - Solubility and stability of the test substance in the solvent/vehicle  - Reactivity of the test substance with the solvent/vehicle or the cell culture medium  TREATMENT OF TEST MATERIAL PRIOR TO TESTING  - Treatment of test material prior to testing (e.g. warming, grinding)  - Preliminary purification step  - Final dilution of a soluble solid, stock liquid, or gel (e.g., neat liquid, stock diluted liquid, or dissolved solid) to final concentration and the solvent(s) used  - Final preparation of a solid (e.g. stock crystals ground to fine powder using a mortar and pestle)  FORM AS APPLIED IN THE TEST (if different from that of starting material)  Specify the relevant form characteristics if different from those in the starting material, such as state of aggregation, shape of particles or particle size distribution.  FORMULATED PRODUCT (for biocides/pesticides)  Description of the formulation, e.g. formulated product for foliar application; formulated product soil application; solution in organic solvent for soil application: formulated product seed treatment; solution in organic solvent seed treatment.  OTHER SPECIFICS  Provide any other relevant information needed for characterising the tested material. |  |
|  | **Test animals** | **Header 2** |  |  |  |
|  | Species | List (picklist)  Display: Basic | **Picklist values:** - mouse - rat - cat - cattle - dog - gerbil - guinea pig - hamster - hamster, Armenian - hamster, Chinese - hamster, Syrian - hen - miniature swine - monkey - pig - primate - rabbit - sheep - other: | Select species as appropriate. If not available from picklist, select 'other' and specify. |  |
|  | Strain | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - AKR - [mouse] - Abyssinian - [guinea pig] - Angora - [rabbit] - B6C3F1 - [mouse] - Balb/c - [mouse] - Beagle - [dog] - Belgian Hare - [rabbit] - Brown Norway - [rat] - C3H - [mouse] - C57BL - [mouse] - CAF1 - [mouse] - CB6F1 - [mouse] - CBA - [mouse] - CD-1 - [mouse] - CF-1 - [mouse] - Californian - [rabbit] - Chinchilla - [rabbit] - Crj: CD(SD) - [rat] - DBA - [mouse] - DBF1 - [mouse] - Dunkin-Hartley - [guinea pig] - Dutch - [rabbit] - FVB - [mouse] - Fischer 344 - [rat] - Fischer 344/DuCrj - [rat] - Flemish Giant - [rabbit] - Hartley - [guinea pig] - Himalayan - [rabbit] - ICL-ICR - [mouse] - ICR - [mouse] - Lewis - [rat] - Long-Evans - [rat] - Macaca fascicularis - [monkey] - Marmoset - [monkey] - Mulatta arctoides - [monkey] - NMRI - [mouse] - New Zealand Black - [rabbit] - New Zealand Red - [rabbit] - New Zealand White - [rabbit] - Nude - [mouse] - Nude Balb/cAnN - [mouse] - Nude CD-1 - [mouse] - Osborne-Mendel - [rat] - Peruvian - [guinea pig] - Pirbright-Hartley - [guinea pig] - Polish - [rabbit] - Rainbow trout - [fish] - SIV 50 - [mouse] - SKH/HR1 - [mouse] - San Juan - [rabbit] - Sencar - [mouse] - Sherman - [rat] - Shorthair - [guinea pig] - Sprague-Dawley - [rat] - Strain A - [mouse] - Swiss - [mouse] - Swiss Webster - [mouse] - Tif:MAGf - [mouse] - Vienna White - [rabbit] - Wistar - [rat] - Wistar Kyoto (WKY) - [rat] - Zucker - [rat] - not specified - other: | Select strain as appropriate. If not available from picklist, select 'other' and specify. |  |
|  | Sex | List (picklist)  Display: Basic | **Picklist values:** - female - male - male/female - not specified | Select as appropriate. If females were used, indicate in field “Details on test animals and environmental conditions” whether nulliparous and non-pregnant. |  |
|  | Details on test animals or test system and environmental conditions | Text template  Display: Detailed | **Freetext template:** TEST ANIMALS  - Source:   - Age at study initiation:   - Weight at study initiation:   - Fasting period before study:   - Housing:   - Diet (e.g. ad libitum):   - Water (e.g. ad libitum):  - Acclimation period:    ENVIRONMENTAL CONDITIONS  - Temperature (°C):   - Humidity (%):   - Air changes (per hr):   - Photoperiod (hrs dark / hrs light):    IN-LIFE DATES: From: To: | Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  Explanations:  - Diet: Describe type of diet (e.g. conventional laboratory diet / caloric restriction) and whether it was provided ad libitum.  - Water: Describe type (e.g. drinking water) and whether it was provided ad libitum.  - Food quality and water quality: provide analytical information on the nutrient and dietary contaminant levels. Similarly provide analytical information on the drinking water used in the study.  - IN-LIFE DATES: If required, specify the in-life dates (i.e. the phase of a study following treatment in which the test system is alive/growing). |  |
|  | **Administration / exposure** | **Header 2** |  |  |  |
|  | Route of administration | List (picklist)  Display: Basic | **Picklist values:** - oral: gavage - oral: capsule - oral: feed - oral: drinking water - oral: unspecified - inhalation: aerosol - inhalation: dust - inhalation: gas - inhalation: mist - inhalation: vapour - inhalation: mixture of gas, vapour and aerosol - inhalation: mixture of vapour and aerosol / mist - inhalation: mixture of gas and vapour - inhalation - dermal - implantation - infusion - intramuscular - intraperitoneal - intratracheal - intravenous - subcutaneous - other: - not specified | Select as appropriate. If not available from picklist, select 'other' and specify. |  |
|  | Vehicle | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - unchanged (no vehicle) - acetone - air - arachis oil - beeswax - carbowaxe - castor oil - cetosteryl alcohol - cetyl alcohol - clean air - CMC (carboxymethyl cellulose) - coconut oil - corn oil - cotton seed oil - DMSO - ethanol - glycerol ester - glycolester - hydrogenated vegetable oil - lecithin - macrogel ester - maize oil - olive oil - oxygen - paraffin oil - peanut oil - petrolatum - physiological saline - poloxamer - polyethylene glycol - propylene glycol - silicone oil - sorbitan derivative - soya oil - theobroma oil - vegetable oil - water - other: - not specified | Select 'unchanged (no vehicle)' if none was used or select vehicle used if any. If not available from picklist, select 'other' and specify. Further information can be given in the supplementary remarks field.  Note that some of the vehicles provided in this list are used for specific routes of administration only. |  |
|  | Mass median aerodynamic diameter (MMAD) | Numeric range (decimal with picklist)  Display: Basic | **Lower numeric field [xx]:** - > - >= - ca. **Upper numeric field [xx]:** - < - <= - ca. **Picklist values:** - nm - µm - mm - other: | For inhalation studies, specify the mass median aerodynamic diameter (MMAD) of the distribution of particle sizes. Enter a single numeric value in the first numeric field if you select no qualifier or '>', '>=' or 'ca.'. Use the second numeric field if the qualifier is '<' or '<='. For a range use both numeric fields together with the appropriate qualifier(s) if applicable. |  |
|  | Geometric standard deviation (GSD) | Numeric (decimal)  Display: Basic |  | Enter a single numeric value in the first numeric field if you select no qualifier or '>', '>=' or 'ca.'. Use the second numeric field if the qualifier is '<' or '<='. For a range use both numeric fields together with the appropriate qualifier(s) if applicable. |  |
|  | Remarks on MMAD | Text (2,000 char.)  Display: Basic |  | Enter any remarks related to the mass median aerodynamic diameter. |  |
|  | Details on exposure | Text template  Display: Detailed | **Freetext template:  Option 1 Route = oral**  PREPARATION OF DOSING SOLUTIONS:    DIET PREPARATION  - Rate of preparation of diet (frequency):  - Mixing appropriate amounts with (Type of food):   - Storage temperature of food:    VEHICLE  - Justification for use and choice of vehicle (if other than water):   - Concentration in vehicle:   - Amount of vehicle (if gavage):   - Lot/batch no. (if required):   - Purity: **Option 2 Route = inhalation**  GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION  - Exposure apparatus:  - Method of holding animals in test chamber:  - Source and rate of air:  - Method of conditioning air:  - System of generating particulates/aerosols:  - Temperature, humidity, pressure in air chamber:   - Air flow rate:   - Air change rate:   - Method of particle size determination:   - Treatment of exhaust air:    TEST ATMOSPHERE  - Brief description of analytical method used:   - Samples taken from breathing zone: yes/no    VEHICLE (if applicable)  - Justification for use and choice of vehicle:   - Composition of vehicle:  - Type and concentration of dispersant aid (if powder):   - Concentration of test material in vehicle:  - Lot/batch no. of vehicle (if required):   - Purity of vehicle: **Option 3 Route = dermal**  TEST SITE  - Area of exposure:   - % coverage:   - Type of wrap if used:   - Time intervals for shavings or clipplings:     REMOVAL OF TEST SUBSTANCE  - Washing (if done):   - Time after start of exposure:    TEST MATERIAL  - Amount(s) applied (volume or weight with unit):  - Concentration (if solution):  - Constant volume or concentration used: yes/no  - For solids, paste formed: yes/no    VEHICLE  - Justification for use and choice of vehicle (if other than water):   - Amount(s) applied (volume or weight with unit):  - Concentration (if solution):  - Lot/batch no. (if required):   - Purity:     USE OF RESTRAINERS FOR PREVENTING INGESTION: yes/no | Select freetext template for the respective type of study and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof. |  |
|  | Analytical verification of doses or concentrations | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - yes - no - not specified | Indicate whether the doses or concentrations were analytically verified. |  |
|  | Details on analytical verification of doses or concentrations | Text (32,768 char.)  Display: Detailed |  | For robust study summaries or as requested by the regulatory programme, include a short description on the method of analysis in the supplementary remarks field. If any problems occurred in any of these procedures, then they should be reported in more detail. If this could have affected the veracity or conclusions of the study, discuss this in field 'Rationale for reliability incl. deficiencies'.  Further route-dependent information to be included:  - For oral studies: State whether the analytical data indicated that the difference between nominal and actual dosage (if diet is route of administration) or concentrations (for drinking water study) was acceptable.  If diet is the route of administration, briefly record when and at what dose levels the dosage analyses were made and include the results (range of values) of (i) Homogeneity analysis, (ii) Stability analysis and (iii) Concentration analysis. It may be appropriate to include a cross-reference to another study in which stability analysis was performed and reported. If so, a justification should also be included briefly explaining the rationale of referring to another study.  - For inhalation studies: State whether the analytical data indicated that the difference between nominal and actual concentrations was acceptable.  - For dermal studies: State whether the analytical data indicated that the difference between nominal and actual concentrations of the test substance in the vehicle was acceptable. |  |
|  | Duration of treatment / exposure | Text (2,000 char.)  Display: Basic |  | Indicate duration in days, weeks or months, e.g. '28 days' or '18 months'. |  |
|  | Frequency of treatment | Text (2,000 char.)  Display: Basic |  | Indicate the frequency of the administration of doses to the test animals (e.g., 'daily, 7 days each week'). Use of non-standard dosing regime (e.g. a five-day per week regime) should be justified. |  |
|  | **Doses / concentrations** | **Block of fields (repeatable) Start** |  | Indicate the dose or concentration levels applied and the basis of quantity used. Copy this block of fields for each numeric value and to record values on a different basis, i.e. mg/kg bw/day (nominal), mg/kg bw/day (actual dose received), mg/kg diet ,mg/L drinking water, mg/kg bw (total dose), ppm if applicable. Conversion of the dose / conc. values to the relevant unit used for the effect levels may be required. |  |
|  | Dose / conc. | Numeric (decimal including unit)  Display: Basic | **Unit [xx]:** - mg/kg bw/day (nominal) - mg/kg bw/day (actual dose received) - mg/kg bw/day - mg/kg diet - mg/L drinking water - mg/kg bw (total dose) - mg/L air - mg/L air (nominal) - mg/L air (analytical) - mg/m³ air - mg/m³ air (nominal) - mg/m³ air (analytical) - ppm - ppm (nominal) - ppm (analytical) - other: - CFU/kg bw/day (actual dose received) - CFU/kg bw/day (nominal) - CFU/kg bw/day - CFU/kg diet - CFU/L drinking water - CFU/kg bw (total dose) - CFU/L air - CFU/m³ air - IU/kg bw/day (actual dose received) - IU/kg bw/day (nominal) - IU//kg bw/day - IU/kg diet - IU/L drinking water - IU/kg bw (total dose) - IU/L air - IU/m³ air - OB/kg bw/day (actual dose received) - OB/kg bw/day (nominal) - OB/kg bw/day - OB/kg diet - OB/L drinking water - OB/kg bw (total dose) - OB/L air - OB/m³ air - spores/kg bw/day (actual dose received) - spores/kg bw/day (nominal) - spores/kg bw/day - spores/kg diet - spores/L drinking water - spores/kg bw (total dose) - spores/L air - spores/m³ air | Enter numeric value. |  |
|  | Remarks | Text (2,000 char.)  Display: Basic |  | Enter any remarks related to dose / concentration values. |  |
|  | **Doses / concentrations** | **Block of fields (repeatable) End** |  |  |  |
|  | No. of animals per sex per dose | Text (2,000 char.)  Display: Basic |  | Enter value or specify according to dose if different number of animals per dose or test, e.g. '10 in each dose group of FOB'.  For robust study summaries or as requested by the regulatory programme, also include a detailed table on the animal assignment in the rich text field 'Any other information on results incl. tables'. Upload predefined or other appropriate table(s) if any and tailor it/them to your needs. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. '... see Table 1').  For a developmental neurotoxicity study it should be noted: The method of animal assignment should have minimized potential problems related to litter effects, i.e., by using one pup/sex/litter (or one measure/litter, e.g., mean body weight for each litter).  When allocating animals to FOB and motor activity testing, the same individual animals should have been evaluated at all scheduled time points.  For the selection of animals and testing paradigms for cognitive (learning and memory) assessment, it is important to ensure that tasks were selected and/or animals allocated so that comparable assessments of learning were made at both times, i.e., shortly after PND 21 and around PND 60. Indicate whether the same or different animals were used for assessments at the weanling and adult ages. In general, the use of separate animals at the two time points is preferred, because for many tasks, initial learning (PND 21) may confound later (PND 60) assessment of learning. If the same animals were used at both times, different tasks would likely have been necessary. The selection of the test for assessing learning should have been adequately justified regardless of whether the same or a different task was used. |  |
|  | Control animals | List multi. (multi-select list with remarks)  Display: Basic | **Picklist values:** - yes - yes, concurrent no treatment - yes, concurrent vehicle - yes, plain diet - yes, sham-exposed - yes, historical - no - other: - not specified | Indicate whether and what type of concurrent control groups were used. Multiple selection is possible. If not listed, select 'other' and specify. |  |
|  | Details on study design | Text template  Display: Detailed | **Freetext template:** - Dose selection rationale:   - Rationale for animal assignment (if not random):   - Rationale for selecting satellite groups:   - Post-exposure recovery period in satellite groups:   - Other: | Include any details on the study design including a brief description of the rationale for dose selection, animal assignment and selection of satellite groups including the duration of the post-exposure recovery period. As appropriate state study type(s) and briefly describe the results from range-finding or other studies used as basis for dose selection. More comprehensive details may be attached.  Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  For a developmental neurotoxicity study it should be noted: Dose selection rationale should be discussed, including information from the prenatal developmental or two-generation reproduction studies, if applicable. Any pilot study data (including biomarker data, such as cholinesterase activity) or pharmacokinetic data (e.g., milk or blood levels of test substance, or data that established time of peak effect) should be described in detail. If these data were submitted in a separate study report, the methods and results (including detailed tables of analytical results) should be presented in a separate record (include a reference in the block 'Cross-reference'); alternatively, they could be appended to this record. |  |
|  | **Examinations** | **Header 2** |  |  |  |
|  | Observations and clinical examinations performed and frequency | Text template  Display: Detailed | **Freetext template:** CAGE SIDE OBSERVATIONS: Yes / No / No data  - Time schedule:   - Cage side observations checked in table [No.?] were included.     DETAILED CLINICAL OBSERVATIONS: Yes / No / No data  - Time schedule:     BODY WEIGHT: Yes / No / No data  - Time schedule for examinations:    FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):   - Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data   - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data    WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data  - Time schedule for examinations:    OPHTHALMOSCOPIC EXAMINATION: Yes / No / No data  - Time schedule for examinations:  - Dose groups that were examined:    OTHER: | Indicate if and which examinations were performed and the time schedule for those examinations. Also indicate the dose groups that were examined if not all. When tabulating parameters examined, refer to respective table no.  If other observations (e.g. haematology) are reported in another study summary (e.g. repeated dose toxicity), include a note in the block 'Cross-reference' and refer to that summary.  Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof. |  |
|  | Specific biochemical examinations | Text template  Display: Detailed | **Freetext template:** NEUROPATHY TARGET ESTERASE (NTE) ACTIVITY: Yes / No / No data  - Time schedule for examinations:   - How many animals:  - Method of sample collection and processing:   - Tissues used:   - Animals fasted: Yes / No / No data  - Description of methodology for NTE determination:   - Other:     CHOLINESTERASE ACTIVITY: Yes / No / No data  - Time schedule for examinations:   - How many animals:  - Method of sample collection and processing:   - Tissues used:   - Animals fasted: Yes / No / No data  - Description of methodology for NTE determination:   - Other:     OTHER: | If specific biochemical determinations were made, provide details on the sampling, the tissues tested (e.g. plasma, whole blood, RBCs, brain (whole brain or regions)) and methodology. When tabulating parameters examined, refer to respective table no.  Use freetext template and delete/add elements as appropriate (e.g. delete items on NTE activity if not applicable). Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof. |  |
|  | Neurobehavioural examinations performed and frequency | Text template  Display: Detailed | **Freetext template:** FUNCTIONAL OBSERVATIONAL BATTERY: [Yes / No / No data] - Parameters checked in table [No.?] were examined. - Description of procedures: - Minimization of bias: - Same technicians used throughout testing: [Yes / No / No data] - Technicians were blind to treatment status of animals: [Yes / No / No data] - Site of testing: - Time schedule for examinations: - Environmental conditions: - Noise level: - Other: - Scoring criteria (if any): - Duration of observation period for open field observations: - Description of equipment where required:   Additional information for developmental neurotoxicity study: - Number of offspring/sex/group examined on postnatal days (unless given in animal assignment table) outside the home cage: - Description of procedures used for each age at which offspring were examined: [adjustments for developmental age / other: ] - Same offspring evaluated at each time point: [no (describe/justify) / yes] - Same parameters assessed in the maternal FOB examined for offspring:   LOCOMOTOR ACTIVITY: [Yes / No / No data] - Replicates used: - Type of equipment used: - Length of session, number and length of subsessions: - Parameters measured: - Total activity: - Ambulatory activity: - Large movements: - Small movements - Other: Additional information for developmental neurotoxicity study: - Number and age of offspring/sex/group examined (unless given in animal assignment table) and days of evaluation: - Description of procedures used for each age at which offspring were examined: [adjustments for developmental age / other: ] - Same offspring evaluated at each preweaning time point: [no (describe/justify) / yes] - Same parameters assessed in the maternal FOB examined for offspring:   Additional testing required for developmental neurotoxicity studies:   AUDITORY STARTLE REFLEX HABITUATION: [Yes / No / No data] - Number of animals: [..] offspring per sex and dose - Days of testing: postnatal days [..] and [..] - Same offspring evaluated at each preweaning time point: [no (describe/justify) / yes] - Exact age: - Type of equipment used: - Environmental conditions: - Number of trials performed: - Length (msec) and intensity (dB) of sound: - Length of interval between trials: - Other procedural details:  LEARNING AND MEMORY TESTING: [Yes / No / No data] (1) Overall testing design - Number of animals: [..] offspring per sex and dose - Days of testing: - Evaluation of both short and long term recall: [yes/no] (2) Equipment used - Type of equipment (including manufacturer, if available): - Environmental conditions: (3) Testing and training procedures - Number of trials per day: - Number of days of testing: - Changes across days: - Inter-trial intervals: - Stimulus parameters: - Use of cut-off times or error correction procedures: - Definition of errors: - Learning criteria: (4) Control procedures - Swim speed in straight alley: - Swimming angle development: (5) Performance measures - Number of errors or trials to criterion: - Time or latency to reach goal: - Performance on "probe trials": | Provide details on the neurobehavioural examinations performed and frequency. Use freetext template and delete/add elements as appropriate (e.g. delete items on NTE activity if not applicable). Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables' and refer to respective table no., e.g. 'see Table 1' (use predefined table if any). Narrative accompanying such tabular data should address the toxicological significance of the results and not repeat what is presented in the table(s). |  |
|  | Sacrifice and (histo)pathology | Text template  Display: Detailed | **Freetext template:** - Time point of sacrifice: - Number of animals sacrificed: - Parameters measured: - Brain weight: - Length and width of brain: - Other: - Procedures for perfusion: - Number of animals perfused: - Tissues evaluated: Parameters checked in table [No.?] were examined. - Type of staining: - Methodology of preparation of sections: - Thickness: - Embedding media: - Number of sections: - Number of animals evaluated from each sex and treatment group: | Indicate details on gross pathological and histopathological examinations. Also indicate those dose groups which were examined.  Use freetext template and delete/add elements as appropriate (e.g. delete items on NTE activity if not applicable). Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables' and refer to respective table no., e.g. 'see Table 1' (use predefined table if any). Narrative accompanying such tabular data should address the toxicological significance of the results and not repeat what is presented in the table(s).  Specific guidance for acute or subchronic neurotoxicity:  Indicate when and how were animals sacrificed, how many were perfused, what parameters were measured (e.g. brain weight, length and width), what were the procedures for perfusion, what tissues were evaluated, what type of staining was used, how were sections prepared (thickness, embedding media, number of sections). How many animals from each sex and treatment group were evaluated?  Specific guidance for developmental neurotoxicity studies: see freetext template.  Tables are optional, particularly for postmortem examinations of the offspring and the specific morphometric measures taken. |  |
|  | Other examinations | Text (32,768 char.)  Display: Detailed |  | Describe any other examinations. |  |
|  | Positive control | Text (2,000 char.)  Display: Detailed |  | Briefly describe the positive control data cited, and its acceptability for use with the current study.  For positive control data to be acceptable, it must demonstrate the sensitivity of the test method to detect changes in the measured parameters. These data do not have to be from studies using prenatal exposures. However, the laboratory must demonstrate competence in evaluation of effects in neonatal animals perinatally exposed to chemicals and establish test norms for the appropriate age group. For observational measures, the data should demonstrate the ability to detect major neurotoxic endpoints, including limb weakness, paralysis, tremor, and autonomic signs; motor activity positive control data should demonstrate the ability to detect both increases and decreases in motor activity; pathology positive control data should demonstrate the ability to detect central and peripheral nervous system pathology (separate groups may be used to demonstrate each type of pathology, for example, acrylamide for peripheral nervous system pathology and trimethyl tin for central nervous system pathology).  The methods should be completely described, and must be the same as those used in the study being evaluated (for example, the same equipment should be used, motor activity sessions should be of the same duration, the observation arena should be the same, the same sections should be evaluated for neuropathology, using the same types of stains, etc.), and preferably the same personnel should have conducted the testing. The data presentation should be complete enough to evaluate the sensitivity of the method, including individual data and measures of variability. Statistical evaluations used to demonstrate sensitivity should also be the same as those used in the study being evaluated. The number of animals per test group should not be greater than that used in the study under evaluation. Positive control data should also demonstrate inter-observer reliability for the FOB (i.e., the same results should be seen regardless of who is doing the observations). The positive control data should have been collected within a reasonable time frame before the current study, e.g., the last few years. New data should also be collected when observational personnel or other critical laboratory elements change. |  |
|  | Statistics | Text (2,000 char.)  Display: Detailed |  | List parameters that were analysed and the statistical methods used; include a statement that the Reviewer considers the analyses used to be appropriate. If inappropriate, provide alternative/rationale. |  |
|  | **Any other information on materials and methods incl. tables** | **Header 2** |  |  | **Guidance for data migration:** This field serves as target field for the removed source fields 'Details on mating procedure (for developmental toxicity study)' and 'Litter observations'. The source field label followed by the value of the field is migrated, separated by double line breaks. |
|  |  | Text (rich-text area)  Display: Basic |  | In this field, you can enter any information on materials and methods, for which no distinct field is available, or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format. You can also upload any htm or html document.  Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields 'Overall remarks' and 'Executive summary' allow rich text entry. |  |
|  | **Results and discussion** | **Header 1** |  |  |  |
|  | **Results of examinations** | **Header 2** |  |  |  |
|  | Clinical signs | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Dermal irritation (if dermal study) | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible. Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s). NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Mortality | List (picklist)  Display: Detailed | **Picklist values:** - mortality observed, treatment-related - mortality observed, non-treatment-related - no mortality observed - not examined - not specified | Indicate whether mortality was observed and whether it was treatment-related or not. |  |
|  | Description (incidence) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence of mortality by sex and dose group.  An explanation should be provided when there was a need to humanely sacrifice animals in pain or showing signs of severe and enduring distress. |  |
|  | Body weight and weight changes | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Food consumption and compound intake (if feeding study) | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Food efficiency | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Water consumption and compound intake (if drinking water study) | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Ophthalmological findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Haematological findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Clinical biochemistry findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Endocrine findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by dose group. At a minimum provide a qualitative description where dose effect related observations were seen.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Urinalysis findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Behaviour (functional findings) | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Where relevant describe functional investigations in relation to motor activity, sensory function, grip strength or bizarre behaviour (e.g. walking backwards).  Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Immunological findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Organ weight findings including organ / body weight ratios | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Gross pathological findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Neuropathological findings | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Histopathological findings: non-neoplastic | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Histopathological findings: neoplastic | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. |  |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Other effects | List (picklist)  Display: Detailed | **Picklist values:** - effects observed, treatment-related - effects observed, non-treatment-related - no effects observed - not examined - not specified | Indicate whether any effects were observed and whether they were treatment-related or not. Select 'not examined' or 'not specified' as applicable. | **Guidance for data migration:** This field serves as target field for the removed source fields under heading 'Further observations for developmental neurotoxicity study':  Reproductive performance (parental animals), Viability (offspring), Sexual maturation (offspring), Developmental landmarks (offspring), Details on results (for developmental neurotoxicity). The following phrase is selected: - 'effects observed, treatment-related' if any of the source fields contains 'yes'. - 'no effects observed' if any field contains ''no effects' - 'not examined' if contained in any source field - 'not specified' if any field contains 'no data', but no other of the above values. |
|  | Description (incidence and severity) | Text (32,768 char.)  Display: Detailed |  | Describe the incidence and severity of effects by sex and dose group. At a minimum provide a qualitative description where dose effect related observations were seen, whether the effects observed are adverse or non-adverse and if the data allows, whether the effects are reversible or irreversible.  Particularly with comprehensive data, include a table in the rich text field 'Any other information on results incl. tables'. Narrative accompanying such tabular data should mainly address the toxicological significance of the results and not repeat the details presented in the table(s).  NOTE: Depending on the regulatory programme some form of a table(s) (predefined table) may be mandatory. |  |
|  | Details on results | Text (32,768 char.)  Display: Detailed |  | Provide any other relevant details if not entered in the specific "Description" fields for the examined parameters. |  |
|  | **Effect levels** | **Header 2** |  |  |  |
|  |  | **Block of fields (repeatable) Start** |  |  |  |
|  | Key result | Check box  Display: Basic |  | Set this flag for identifying the key information which is of potential relevance for hazard/risk assessment or classification purpose.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. |  |
|  | Dose descriptor | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - NOAEC - NOAEL - NOEC - NOEL - LOAEC - LOAEL - LOEC - LOEL - BMD05 - BMDL05 - BMDL10 - BMD: - BMC05 - BMCL05 - BMCL10 - BMC: - dose level: - conc. level: - other: | Select the relevant dose descriptor, i.e. the exposure level that corresponds to a quantified level of effects, e.g. NOAEL or LOAEL. If a benchmark dose / concentration was calculated, select appropriate BMD indicator (e.g. 'BMD05' or 'BMD:' and specify in the related text field). If the critical effects at a specific dose or concentration level are reported only, select 'dose. level:' or 'conc. level:' and specify.  Where no value could be achieved based on the method and boundaries used, the upper or lower dose level for the relevant dose descriptor can be reported as appropriate with relevant qualifier, e.g. NOAEL >200 mg/kg bw/day or NOAEL <200 mg/kg bw/day. An additional explanation may be given in field 'Remarks on result', e.g. 'not determinable due to absence of adverse toxic effects'. | **Guidance for data migration:** The source field 'Generation (if applicable)' has been removed because Developmental neurotoxicity is now covered by Reproductive toxicity. Entries in this field are migrated to the field 'Remarks on result' with the default entry 'Generation: <source value> (migrated information)'. |
|  | Effect level | Numeric range (decimal with picklist)  Display: Basic | **Lower numeric field [xx]:** - > - >= - ca. **Upper numeric field [xx]:** - < - <= - ca. **Picklist values:** - mg/kg bw/day (nominal) - mg/kg bw/day (actual dose received) - mg/kg bw/day - mg/kg diet - mg/L drinking water - mg/kg bw (total dose) - mg/L air - mg/L air (nominal) - mg/L air (analytical) - mg/m³ air - mg/m³ air (nominal) - mg/m³ air (analytical) - ppm - ppm (nominal) - ppm (analytical) - other: - CFU/kg bw/day (actual dose received) - CFU/kg bw/day (nominal) - CFU/kg bw/day - CFU/kg diet - CFU/L drinking water - CFU/kg bw (total dose) - CFU/L air - CFU/m³ air - IU/kg bw/day (actual dose received) - IU/kg bw/day (nominal) - IU//kg bw/day - IU/kg diet - IU/L drinking water - IU/kg bw (total dose) - IU/L air - IU/m³ air - OB/kg bw/day (actual dose received) - OB/kg bw/day (nominal) - OB/kg bw/day - OB/kg diet - OB/L drinking water - OB/kg bw (total dose) - OB/L air - OB/m³ air - spores/kg bw/day (actual dose received) - spores/kg bw/day (nominal) - spores/kg bw/day - spores/kg diet - spores/L drinking water - spores/kg bw (total dose) - spores/L air - spores/m³ air | Enter a single numeric value in the first numeric field if you select no qualifier or '>', '>=' or 'ca.'. Use the second numeric field if the qualifier is '<' or '<='. For a range use both numeric fields together with the appropriate qualifier(s) if applicable. |  |
|  | Based on | List sup. (picklist with remarks)  Display: Basic | **Picklist values:** - test mat. - test mat. (total fraction) - test mat. (dissolved fraction) - act. ingr. - act. ingr. (total fraction) - act. ingr. (dissolved fraction) - element - element (total fraction) - element (dissolved fraction) - other: - not specified | Indicate whether the concentration is based on the test material (test mat.), active ingredient (act. ingr.) or element. As appropriate the measured / addressed fraction can be specified for either of these entities by selecting the relevant item, e.g. 'element (dissolved fraction)' or 'test mat. (total fraction)'. Further information can be given in the supplementary remarks field, e.g. for specifying the type of fraction if it is not clear per se from the test material specification.  Select 'not specified' if the effect concentration type is not known. |  |
|  | Sex | List (picklist)  Display: Basic | **Picklist values:** - female - male - male/female - not specified | Select from drop-down list. |  |
|  | Basis for effect level | List multi. (multi-select list with remarks - 32,000 char.)  Display: Basic | **Picklist values:** - behaviour (functional findings) - body weight and weight gain - clinical biochemistry - clinical signs - dermal irritation - food consumption and compound intake - food efficiency - gross pathology - haematology - histopathology: neoplastic - histopathology: non-neoplastic - immunology - mortality - neuropathology - ophthalmological examination - organ weights and organ / body weight ratios - serum/plasma biochemistry - serum/plasma hormone analyses - sperm measures - urinalysis - water consumption and compound intake - other endocrine activity endpoints - other: | Indicate the parameter(s) used to establish the given effect level. Multi-selection of different pre-defined values is possible. If none is available, you can select 'other:'. Any explanations can always be entered in the related supplementary text field. |  |
|  | Remarks on result | List sup. (picklist with remarks - 2,000 char.)  Display: Basic | **Picklist values:** - not determinable due to absence of adverse toxic effects - not determinable - not determinable because of methodological limitations - not measured/tested - other: | This field can be used for:  - giving a qualitative description of results in addition to or if no numeric value(s) were derived;  - giving a pre-defined reason why no numeric value is provided, e.g. by selecting 'not determinable' and entering free text explanation in the supplementary remarks field; or  - entering any additional information on the effect level by selecting 'other:' | **Guidance for data migration:** The source field 'Generation (if applicable)' has been removed because Developmental neurotoxicity is now covered by Reproductive toxicity. Entries in this field are migrated to the field 'Remarks on result' with the default entry 'Generation: <source value> (migrated information)'. |
|  |  | **Block of fields (repeatable) End** |  |  |  |
|  | **Target system / organ toxicity** | **Header 2** |  |  |  |
|  |  | **Block of fields (repeatable) Start** |  | Record the target system(s) where toxicity was observed that is considered of biological relevance and the specific target organ(s).  Copy this block of fields for referring to different target systems, lowest effective dose(s) / concentration(s) and/or treatment relationship, dose response relationship and relevance for humans. |  |
|  | Key result | Check box  Display: Basic |  | Set this flag for identifying the key information which is of potential relevance for hazard/risk assessment or classification purpose.  Consult any programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) on how to use this field. |  |
|  | Critical effects observed | List (picklist)  Display: Basic | **Picklist values:** - yes - no - not specified | Flag to indicate if critical effects were observed in the study within specific organs or systems. |  |
|  | Lowest effective dose / conc. | Numeric (decimal including unit)  Display: Basic | **Unit [xx]:** - mg/kg bw/day (nominal) - mg/kg bw/day (actual dose received) - mg/kg bw/day - mg/kg diet - mg/L drinking water - mg/kg bw (total dose) - mg/L air - mg/L air (nominal) - mg/L air (analytical) - mg/m³ air - mg/m³ air (nominal) - mg/m³ air (analytical) - ppm - ppm (nominal) - ppm (analytical) - other: - CFU/kg bw/day (actual dose received) - CFU/kg bw/day (nominal) - CFU/kg bw/day - CFU/kg diet - CFU/L drinking water - CFU/kg bw (total dose) - CFU/L air - CFU/m³ air - IU/kg bw/day (actual dose received) - IU/kg bw/day (nominal) - IU//kg bw/day - IU/kg diet - IU/L drinking water - IU/kg bw (total dose) - IU/L air - IU/m³ air - OB/kg bw/day (actual dose received) - OB/kg bw/day (nominal) - OB/kg bw/day - OB/kg diet - OB/L drinking water - OB/kg bw (total dose) - OB/L air - OB/m³ air - spores/kg bw/day (actual dose received) - spores/kg bw/day (nominal) - spores/kg bw/day - spores/kg diet - spores/L drinking water - spores/kg bw (total dose) - spores/L air - spores/m³ air | Enter a numeric value and select the unit in the next field for indicating the lowest dose / concentration with significant and/or severe toxic effects on the target organ(s) affected. |  |
|  | System | List (picklist)  Display: Basic | **Picklist values:** - autonomic nervous system - cardiovascular - central nervous system - ear - endocrine system - eye - female reproductive system - gastrointestinal tract - haematopoietic - hepatobiliary - immune system - integumentary - male reproductive system - musculoskeletal system - nervous system - peripheral nervous system - respiratory system: lower respiratory tract - respiratory system: upper respiratory tract - somatic nervous system - urinary - other: | Select any specific system where toxicity was observed that is considered of biological relevance. |  |
|  | Organ | List multi. (multi-select list)  Display: Basic | **Picklist values:** - abdominal cavity - adrenal glands - alveolar duct - alveoli - ampulla - aorta - appendix - artery - bile duct - bladder - blood - blood vessel - bone - bone marrow - brain - bronchi - bronchioles - bulbourethral gland - caput - carotid artery - cartilage - cauda epididymis - cervix - choroid - ciliary body - clitoral gland - coagulating gland - cochlea - colon - cornea - corpus - corpus penis - Cowper’s glands - diaphragm - dorsolateral prostate gland - duodenum - erythrocyte development - fallopian tubes - forebrain - gall bladder - gametes - germ cells - glans penis - gonad - hard palate - heart - hindbrain - ileum - intestine - iris - islet of Langerhans - jejunum - kidney - lacrimal gland - larynx - lens - leucocyte development - Levatorani plus bulbocavernous muscle complex - Leydig cells - liver - lungs - lymph node - lymphoreticular tissue - mammary gland - mesenteric lymph node - midbrain - mucosa-associated lymphoid tissue - myofibres - myofilaments - nasal cavity - neurons - non-sensory epithelia - not specified - oesophagus - oral cavity - ovary - oviduct - pancreas - parathyroid gland - parotid gland - penile urethra - peritoneum - pharynx - pineal gland - pituitary gland - placenta - platelet formation - pleura - preputial gland - rectum - retina - salivary glands - sclera - seminal vesicle - seminiferous tubules - Sertoli cells - skin - skin associated lymphoid tissue - spinal cord - spleen - sternum - stomach - sublingual gland - submandibular gland - tendon - testes - thoracic cavity - thymus - thyroid gland - tongue - tooth - trachea - ureter - urethra - uterus - vagina - vas deferens - vascular system - vein - ventral prostate gland - vestibular system - vitreous humour - zymbal gland - other: | Select from the multiple drop-down list the target organ(s) where toxicity was observed. This field provides context-related picklist values depending on the selection made in the preceding field 'System'. |  |
|  | Treatment related | List (picklist)  Display: Basic | **Picklist values:** - yes - no - not specified | Flag to indicate if the effects in systems and/or organs are treatment related. | **Guidance for field condition:** Condition: Field active only if 'Critical effects observed' is 'yes' |
|  | Dose response relationship | List (picklist)  Display: Basic | **Picklist values:** - yes - no - not specified | Flag to indicate if the effects observed and reported in systems and/or organs are in a dose-response manner. | **Guidance for field condition:** Condition: Field active only if 'Critical effects observed' is 'yes' |
|  | Relevant for humans | List (picklist)  Display: Basic | **Picklist values:** - yes - no - not specified - presumably yes | Flag to indicate if the effects observed and reported in systems and/or organs on the basis of animal experiments are also relevant for humans. Choose “no” from the picklist if the effects in target system/organ are species specific and not relevant for humans. | **Guidance for field condition:** Condition: Field active only if 'Critical effects observed' is 'yes' |
|  |  | **Block of fields (repeatable) End** |  |  |  |
|  | **Any other information on results incl. tables** | **Header 2** |  |  |  |
|  |  | Text (rich-text area)  Display: Basic |  | In this field, you can enter any other remarks on results. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.  Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields 'Overall remarks' and 'Executive summary' allow rich text entry. |  |
|  | **Overall remarks, attachments** | **Header 1** |  |  |  |
|  | Overall remarks | Text (rich-text area)  Display: Basic |  | In this field, you can enter any overall remarks or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format. You can also upload any htm or html document.  Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields 'Overall remarks' and 'Executive summary' allow rich text entry. |  |
|  | **Attachments** | **Block of fields (repeatable) Start** |  | Attach any background document that cannot be inserted in any rich text editor field, particularly image files (e.g. an image of a structural formula).  Copy this block of fields for attaching more than one file. |  |
|  | Type | List (picklist)  Display: Basic | **Picklist values:** - full study report - other: | Specify the type of attachment inserted, for example the 'full study report'. |  |
|  | Attached (confidential) document | Attachment (single)  Display: Basic (Confidential) |  | An electronic copy of the full study report or other documents can be attached as Word, pdf or other file types. |  |
|  | Attached (sanitised) documents for publication | Attachment (single)  Display: Basic |  | An electronic copy of a public (non-confidential) version of the full study report or other relevant documents can be attached. This attachment should be sanitised if needed. |  |
|  | Remarks | Text (255 char.)  Display: Basic |  | As appropriate, include remarks, e.g. a short description of the content of the attached document if the file name is not self-explanatory. |  |
|  | **Attachments** | **Block of fields (repeatable) End** |  |  |  |
|  | Illustration (picture/graph) | Image upload  Display: Basic |  | Upload file by clicking the upload icon. As appropriate, enter any additional information, e.g. language. The file name is displayed after uploading the document. |  |
|  | **Applicant's summary and conclusion** | **Header 1** |  |  |  |
|  | Conclusions | Text (32,768 char.)  Display: Basic |  | Enter any conclusions if applicable in addition to the information given in fields 'Key results' and 'Interpretation of results' (if any). |  |
|  | Executive summary | Text (rich-text area)  Display: Basic |  | If relevant for the respective regulatory programme, briefly summarise the relevant aspects of the study including the conclusions reached. If a specific format is prescribed, copy it from the corresponding document or upload it if provided as htm or html document.  Consult the programme-specific guidance (e.g. OECD Programme, Pesticides NAFTA or EU REACH) thereof. |  |